ClinicalTrials.gg
CompletedNCT07847593ProSemUpdated Oct 8, 2026

Probiotics in Obese Patients Treated With Semaglutide

An interventional study of Four-strain probiotic formulation and Maltodextrin (Placebo) in Obesity (Disorder), GLP-1 Receptor Agonist Treatment and Probiotic Intervention, sponsored by Nordic Biotic Sp. z o.o.. Completed at 3 sites in Poland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Nordic Biotic Sp. z o.o. · Not applicable, Interventional, and Supportive care

How we know · 5 judgments

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Jul 2025, registered Sep 2026).
Updated Oct 8, 2026Eligibility revisedPrimary outcomes revised+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 162 studies in Obesity with a site in Poland — 46 open to participants now, 73 under way, 44 of them phase 3. Obesity · Poland.

Enrollment
98th of 136
102 · median 334
Started
2025
with 27 others
No phase
50 of 162
9 open now
Registered
158th of 162
by date

Among the 162 studies in Obesity with a site in Poland, this one is the 98th largest by enrollment of the 136 interventional ones that give a count, is one of 28 that started in 2025, is one of 50 with no phase, and was the 158th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

46 of the 162 studies in Obesity with a site in Poland are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Obesity with a site in Poland, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled trial evaluated the effects of a four-strain probiotic formulation in adults with obesity receiving semaglutide. Participants received either the probiotic formulation or placebo, beginning two weeks before semaglutide initiation and continuing throughout the 12-week semaglutide-treatment and dose-escalation period. The primary objective was to determine whether probiotic supplementation reduced gastrointestinal adverse events associated with semaglutide treatment. The primary outcome comprised two complementary measures during the 12-week semaglutide-treatment period: the proportion of participants reporting at least one protocol-defined gastrointestinal adverse event during scheduled study visits and the proportion of evaluable treatment days on which a participant reported at least one protocol-defined gastrointestinal adverse event in the daily diary. Secondary outcomes included gastrointestinal symptom severity, the number of days with individual gastrointestinal adverse events, health-related quality of life, change in body weight, treatment discontinuation, and inability to escalate the semaglutide dose as planned. Additional gastrointestinal complaints and non-gastrointestinal symptoms were monitored as part of safety assessment.

Read the detailed description

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide, are effective pharmacological treatments for obesity. Semaglutide acts through multiple mechanisms, including enhancement of satiety, reduction of appetite, slowing of gastric emptying, stimulation of glucose-dependent insulin secretion, and suppression of glucagon secretion. Clinical studies have demonstrated that semaglutide can produce clinically meaningful body weight reduction and improve glycemic and other cardiometabolic outcomes. However, treatment is frequently associated with gastrointestinal adverse events, particularly during dose escalation. Commonly reported gastrointestinal adverse events include nausea, vomiting, diarrhea, constipation, abdominal pain, and bloating.

The gut microbiota may influence gastrointestinal function, intestinal barrier integrity, host metabolism, and inflammatory processes. Selected probiotic strains may therefore have the potential to support gastrointestinal function and improve treatment tolerability. This provided the rationale for evaluating a specifically selected probiotic formulation as a supportive intervention in adults with obesity receiving semaglutide.

This was a randomized, double-blind, placebo-controlled, parallel-group interventional trial conducted in adults with obesity. Participants were randomly assigned to receive either a four-strain probiotic formulation or a matching placebo. The probiotic formulation contained Bifidobacterium animalis subsp. lactis AZHx1, Limosilactobacillus reuteri AZHx2, Lacticaseibacillus casei AZHx3, and Lacticaseibacillus rhamnosus AZHx4.

The assigned probiotic or placebo was initiated two weeks before the first dose of semaglutide and continued throughout the subsequent 12-week semaglutide-treatment period. Semaglutide was administered once weekly according to a stepwise dose-escalation schedule: 0.25 mg during weeks 1-4, 0.5 mg during weeks 5-8, and 1.0 mg during weeks 9-12.

Gastrointestinal tolerability was assessed using two complementary sources of information: investigator assessments performed at scheduled study visits and prospective daily symptom reporting by participants using diaries. Visit V1 marked semaglutide initiation after the scheduled assessment, and follow-up assessments were performed at Visits V2-V4 during the subsequent 12-week dose-escalation period. Participant diaries provided daily observations throughout 2 weeks of pretreatment probiotic/placebo supplementation and the 12 weeks of semaglutide treatment.

The co-primary outcomes were two complementary measures assessed during the 12-week semaglutide-treatment period:

  1. Gastrointestinal adverse event incidence proportion, defined as the percentage of participants reporting at least one protocol-defined gastrointestinal adverse event during the 7-day recall windows preceding scheduled follow-up visits V2-V4; and
  2. Gastrointestinal adverse event prevalence, defined for each participant as the percentage of evaluable semaglutide-treatment days on which at least one protocol-defined gastrointestinal adverse event was recorded in the daily diary.

Protocol-defined gastrointestinal adverse events included nausea, vomiting, diarrhea, constipation, abdominal pain, and bloating.

Secondary outcomes included the severity of individual gastrointestinal symptoms, the number of days with individual protocol-defined gastrointestinal adverse events, health-related quality of life, change in body weight, discontinuation of semaglutide treatment, and inability to escalate the semaglutide dose according to the planned schedule. Additional gastrointestinal complaints and non-gastrointestinal symptoms were monitored as part of safety assessment. Outcomes were compared between participants receiving semaglutide in combination with the probiotic formulation and those receiving semaglutide in combination with placebo.

03

Conditions studied

  • Obesity (Disorder)
  • GLP-1 Receptor Agonist Treatment
  • Probiotic Intervention
  • Diabetes Mellitus Type 2

Keywords

  • Obesity
  • GLP-1 receptor agonist treatment
  • Gatro-intestinal adverse events
  • Probiotics
  • Diabetes mellitus type 2
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) of at least 30 kg/m², with or without coexisting type 2 diabetes mellitus;
  • patients initiating treatment with a glucagon-like peptide-1 receptor agonist;
  • provided written ;
  • patients with ability to adhere to the investigators' instructions regarding study protocol and procedures.

Exclusion criteria

Exclusion criteria:

  • patients with gastrointestinal conditions unrelated to glucagon-like peptide-1 receptor agonist therapy, such as inflammatory bowel diseases, celiac disease, irritable bowel syndrome, gastroenteritis, gastric and duodenal ulcers, parasitic or bacterial intestinal infestation/infections,
  • known food allergies and lactose intolerance,
  • severe neurological conditions, , and hepatic or renal impairment,
  • pregnancy or breastfeeding,
  • anemia and leukocytosis in laboratory tests,
  • the use of intestine microbiota-targeted dietary supplements or drugs (i.e. probiotics, prebiotics, synbiotics, or postbiotics including butyric acid) within the last 3 months,
  • the use of antibiotics within the last 1 month,
  • the use of the following drugs: insulin, glucocorticosteroids, proton pump blockers,
  • a surgical procedure scheduled during the clinical study,
  • being enrolled in another clinical trial within the last 3 months,
  • alcohol or substance abuse.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Probiotic

    Participants assigned to this arm received the probiotic formulation in addition to semaglutide treatment.

    Dietary Supplement: Four-strain probiotic formulation

  • Placebo comparator
    Placebo

    Participants assigned to this arm received a matching placebo containing maltodextrin in addition to semaglutide treatment.

    Dietary Supplement: Maltodextrin (Placebo)

Interventions

  • Dietary supplementFour-strain probiotic formulation

    The probiotic formulation contained Bifidobacterium animalis subsp. lactis AZHx1 (DSM 35201), Limosilactobacillus reuteri AZHx2 (DSM 35202), Lacticaseibacillus casei AZHx3 (DSM 35185), and Lacticaseibacillus rhamnosus AZHx4 (DSM 35757). It was administered orally in capsule form twice daily, at a total daily dose of 80 billion colony-forming units. Supplementation was initiated two weeks before the first dose of semaglutide and continued throughout the subsequent 12-week semaglutide-treatment and dose-escalation period, resulting in a total supplementation period of 14 weeks.

  • Dietary supplementMaltodextrin (Placebo)

    The placebo contained maltodextrin and was matched to the probiotic formulation in appearance, packaging, and administration schedule. It was administered orally in capsule form twice daily for 14 weeks, beginning two weeks before the first dose of semaglutide and continuing throughout the subsequent 12-week semaglutide-treatment and dose-escalation period.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Gastrointestinal adverse event incidence proportion during semaglutide treatment

    The gastrointestinal adverse event incidence proportion was defined as the percentage of participants reporting at least one protocol-defined gastrointestinal adverse event during the 7-day recall windows preceding Visits V2-V4 over the 12-week semaglutide-treatment period. Gastrointestinal adverse events included nausea, vomiting, diarrhea, constipation, abdominal pain, and bloating. Each participant was counted once, regardless of whether the symptom was reported at more than one visit or had been present before semaglutide initiation. The possible range was 0%-100%, with higher values indicating a higher proportion of participants reporting gastrointestinal adverse events.

    Time frame: During the 12-week semaglutide treatment and dose-escalation period

  2. Prevalence of gastrointestinal adverse events during semaglutide treatment

    Gastrointestinal adverse event prevalence was defined for each participant as the percentage of evaluable days during the 12-week semaglutide-treatment period on which at least one protocol-defined gastrointestinal adverse was recorded in the daily diary. Gastrointestinal adverse events included nausea, vomiting, diarrhea, constipation, abdominal pain, and bloating. A day with more than one gastrointestinal adverse event was counted once for the overall prevalence. Prevalence was calculated as the number of evaluable days with at least one gastrointestinal adverse event divided by the total number of evaluable days for that participant, multiplied by 100. Group results were summarized as the mean participant-level prevalence. The possible range was 0%-100%.

    Time frame: During the 12-week semaglutide treatment and dose-escalation period

Secondary outcomes

  1. Change in Health-Related Quality of Life

    Health-related quality of life was assessed using the the 36-Item Short Form Health Survey, version 2 (SF-36v2) at baseline, before initiation of semaglutide treatment, and at the end of the 12-week semaglutide-treatment period. SF-36v2 scores were calculated using the licensed IQVIA PRO CoRE scoring software according to the standardized scoring algorithm. The assessment included the eight health domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional, and Mental Health, as well as the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Changes from baseline to Week 12 were evaluated and compared between treatment groups. Higher scores indicate better health-related quality of life.

    Time frame: Baseline (before initiation of semaglutide treatment) and Week 12 (end of semaglutide treatment)

  2. Severity of Selected Gastrointestinal Adverse Events

    The severity of three selected gastrointestinal adverse events-abdominal pain, bloating and nausea-was assessed during the 12-week semaglutide-treatment period. Symptom severity was assessed at scheduled study visits and was also recorded prospectively by participants in daily diaries throughout the treatment period. For each of the three symptoms, severity was rated using a 4-point Likert scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe. Higher scores indicated greater symptom severity. Severity of the individual symptoms was compared between the probiotic and placebo groups.

    Time frame: From initiation of semaglutide treatment through Week 12

  3. Number of Days With Individual Gastrointestinal Symptoms

    The number of days with individual gastrointestinal adverse events was assessed prospectively using participant-completed daily diaries during the 12-week semaglutide-treatment period. Events included abdominal pain, bloating, nausea, diarrhea, constipation, and vomiting. Abdominal pain, bloating, and nausea were rated daily on a 4-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe); scores greater than 0 indicated symptom presence, and scores of 2 or 3 indicated moderate or severe symptoms. Diarrhea and constipation were defined using the Bristol Stool Form Scale as stool types 6-7 and 1-2, respectively; vomiting required an explicit diary entry. For each participant, the number of days with each individual gastrointestinal adverse event was determined. For abdominal pain, bloating, and nausea, the number of days with moderate or severe symptoms (severity score ≥2) was also determined. Higher numbers of symptomatic days indicated a greater gastrointestinal symptom burden.

    Time frame: From initiation of semaglutide treatment through Week 12

  4. Change in Body Weight During Semaglutide Treatment

    Body weight was measured by the investigator at each scheduled study visit during the 12-week semaglutide-treatment and dose-escalation period. Change in body weight from baseline, defined as the assessment before initiation of semaglutide treatment, was evaluated over time and at Week 12. Body weight was measured in kilograms, with greater decreases from baseline indicating greater weight loss. Changes in body weight were compared between the probiotic and placebo groups.

    Time frame: Baseline (before initiation of semaglutide treatment) and during scheduled study visits through Week 12

  5. Number of Participants Who Discontinued Semaglutide Treatment

    The number of participants who discontinued semaglutide treatment for any reason during the 12-week treatment and dose-escalation period was recorded. Treatment discontinuation was assessed by investigators at scheduled study visits. The outcome was expressed as the number and proportion of participants who discontinued semaglutide before completion of the 12-week treatment period.

    Time frame: From initiation of semaglutide treatment through Week 12

  6. Number of Participants Unable to Escalate Semaglutide Dose According to the Planned Schedule

    The number of participants who were unable to escalate the semaglutide dose according to the planned treatment schedule was recorded during the 12-week treatment period. The planned dose-escalation schedule was 0.25 mg once weekly during Weeks 1-4, 0.5 mg once weekly during Weeks 5-8, and 1.0 mg once weekly during Weeks 9-12. Failure to escalate was defined as inability to advance to the next planned dose level according to the study schedule. The outcome was expressed as the number and proportion of affected participants.

    Time frame: From initiation of semaglutide treatment through Week 12

07

Study locations

3 sites
  • The Clinic Centrum Medyczne
    Gdynia, 81-521, Poland
  • Prywatna Specjalistyczna Praktyka Lekarska
    Grudziądz, 86-300, Poland
  • NEUROMEDIKA Indywidualna Specjalistyczna Praktyka Lekarska
    Pruszcz Gdański, 83-000, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Jul 2026, 12 months.

Of 164 industry-sponsored interventional studies with no phase under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 27. This study's 12 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartActual
Jul 9, 2025
Primary completionActual
Jul 15, 2026
CompletionActual
Jul 15, 2026
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
2 inclusion criteria added, 2 removed; 1 exclusion criterion edited
What changed in the criteria
Inclusion criteria
  • RemovedBMI ≥ 30 kg/m² without T2DM or with coexisting T2DM;
  • Removedpatients starting GLP-1RA treatment;
  • AddedBody Mass Index (BMI) of at least 30 kg/m², with or without coexisting type 2 diabetes mellitus;
  • Addedpatients initiating treatment with a glucagon-like peptide-1 receptor agonist;
Exclusion criteria
  • ChangedBefore patients with gastrointestinal conditions unrelated to GLP-1RA therapy,Now patients with gastrointestinal conditions unrelated to glucagon-like peptide-1 receptor agonist therapy, such as inflammatory bowel diseases, celiac disease, irritable bowel syndrome, gastroenteritis, gastric and duodenal ulcers, parasitic or bacterial intestinal infestation/infections,
Oct 8, 2026
Primary outcomes
1 edited, 1 description edited
What changed in the outcomes
  • EditedCumulativeGastrointestinal adverse event incidence proportion of gastrointestinal adverse events during semaglutide treatmentTime frame: During the 12-week semaglutide treatment and dose-escalation period
  • DescriptionPrevalence of gastrointestinal adverse events during semaglutide treatment: how it is measured was reworded
Oct 8, 2026
Secondary outcomes
2 edited, 2 description edited
What changed in the outcomes
  • EditedChange in Health-Related Quality of Life (SF-36v2)Time frame: Baseline (before initiation of semaglutide treatment) and Week 12 (end of semaglutide treatment)
  • EditedSeverity of Selected Gastrointestinal Adverse Events (GI-AEs)Time frame: From initiation of semaglutide treatment through Week 12
  • DescriptionChange in Body Weight During Semaglutide Treatment: how it is measured was reworded
  • DescriptionNumber of Days With Individual Gastrointestinal Symptoms: how it is measured was reworded
Oct 8, 2026
Title
Probiotics in Obese Patients Treated With GLP-1 Receptor AgonistsSemaglutide
Oct 8, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Oct 8, 2026
    Eligibility 2 inclusion criteria added, 2 removed; 1 exclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • RemovedBMI ≥ 30 kg/m² without T2DM or with coexisting T2DM;
    • Removedpatients starting GLP-1RA treatment;
    • AddedBody Mass Index (BMI) of at least 30 kg/m², with or without coexisting type 2 diabetes mellitus;
    • Addedpatients initiating treatment with a glucagon-like peptide-1 receptor agonist;
    Exclusion criteria
    • ChangedBefore patients with gastrointestinal conditions unrelated to GLP-1RA therapy,Now patients with gastrointestinal conditions unrelated to glucagon-like peptide-1 receptor agonist therapy, such as inflammatory bowel diseases, celiac disease, irritable bowel syndrome, gastroenteritis, gastric and duodenal ulcers, parasitic or bacterial intestinal infestation/infections,
    Primary outcomes 1 edited, 1 description edited
    What changed in the outcomes
    • EditedCumulativeGastrointestinal adverse event incidence proportion of gastrointestinal adverse events during semaglutide treatmentTime frame: During the 12-week semaglutide treatment and dose-escalation period
    • DescriptionPrevalence of gastrointestinal adverse events during semaglutide treatment: how it is measured was reworded
    Secondary outcomes 2 edited, 2 description edited
    What changed in the outcomes
    • EditedChange in Health-Related Quality of Life (SF-36v2)Time frame: Baseline (before initiation of semaglutide treatment) and Week 12 (end of semaglutide treatment)
    • EditedSeverity of Selected Gastrointestinal Adverse Events (GI-AEs)Time frame: From initiation of semaglutide treatment through Week 12
    • DescriptionChange in Body Weight During Semaglutide Treatment: how it is measured was reworded
    • DescriptionNumber of Days With Individual Gastrointestinal Symptoms: how it is measured was reworded
    Title Probiotics in Obese Patients Treated With GLP-1 Receptor AgonistsSemaglutide
    + 2 other changes: verification date and description
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07847593
Lead sponsor
Nordic Biotic Sp. z o.o.
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Jul 9, 2025
Primary completion
Jul 15, 2026
Completion
Jul 15, 2026
Last update
Oct 8, 2026

Study contacts

Dagmara Hering, Prof. MD, PhD
principal investigator · Medical University of Gdansk, Department of Hypertension and Diabetology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion